Cellomics May Turn Fisher Into Multi-Platform Rival; Will Dharmacon s RNAi Give It an Edge? | GenomeWeb

As part of its ongoing effort to increase its presence in the multi-platform life sciences instrumentation market, laboratory supply and service giant Fisher Scientific will acquire high-content screening pioneer Cellomics for approximately $49 million in cash, Fisher said last week.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.